Results 1 to 10 of about 1,029,181 (225)

Pharmacokinetics of N,N-dimethyltryptamine in Humans. [PDF]

Eur J Drug Metab Pharmacokinet, 2023
N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the preclinical and clinical pharmacokinetics and metabolism of DMT in healthy subjects.The physiochemical properties of DMT were determined using a series of in vitro experiments and its metabolic profile ...
Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, Weaver R, Allen G, Hughes C, Topping H, Bowman A, James E.   +11 more
europepmc   +4 more sources

Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience [PDF]

Scientific Reports, 2022
Understanding the phenomenology and content of the inhaled N, N, dimethyltryptamine (N, N-DMT) experience is critical to facilitate and support ongoing research and therapeutic models targeting mental health conditions and central nervous system ...
David Wyndham Lawrence, Robin Carhart-Harris, Roland Griffiths, Christopher Timmermann   +3 more
doaj   +3 more sources

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT) [PDF]

Communications Biology
The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects. We use a time-dependent whole-brain model to reproduce large-scale brain dynamics measured with fMRI from
Juan Ignacio Piccinini, Yonatan Sanz Perl, Carla Pallavicini, Gustavo Deco, Morten Kringelbach, David Nutt, Robin Carhart-Harris, Christopher Timmermann, Enzo Tagliazucchi   +8 more
doaj   +3 more sources

N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine. [PDF]

Hum Psychopharmacol, 2022
AbstractObjectiveReports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare.
James E, Keppler J, L Robertshaw T, Sessa B.   +3 more
europepmc   +6 more sources

Neuropharmacology of N,N-dimethyltryptamine [PDF]

Brain Research Bulletin, 2016
N,N-dimethyltryptamine (DMT) is an indole alkaloid widely found in plants and animals. It is best known for producing brief and intense psychedelic effects when ingested. Increasing evidence suggests that endogenous DMT plays important roles for a number of processes in the periphery and central nervous system, and may act as a neurotransmitter.
Michael B Gatch
exaly   +4 more sources

N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk [PDF]

Alzheimer’s Research & Therapy
Background Aberrant neuronal Sigma-1 receptor (Sig-1r)-mediated endoplasmic reticulum (ER)- mitochondria signaling plays a key role in the neuronal cytopathology of Alzheimer’s disease (AD).
Dan Cheng, Zhuo-Gui Lei, Kin Chu, Oi Jin Honey Lam, Chun Yuan Chiang, Zhang-Jin Zhang   +5 more
doaj   +4 more sources

Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT) [PDF]

Frontiers in Pharmacology
The modulation of social cognition is suggested as a possible mechanism contributing to the potential clinical efficacy of psychedelics in disorders involving socio-emotional and reward processing deficits.
Carla Soares, Carla Soares, Gisela Lima, Gisela Lima, Marta Lapo Pais, Marta Teixeira, Célia Cabral, Célia Cabral, Célia Cabral, Miguel Castelo-Branco, Miguel Castelo-Branco   +10 more
doaj   +3 more sources

Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials [PDF]

Frontiers in Psychiatry
IntroductionPsychedelic agents have regained the attention of pharmaceutical companies as promising treatments for depressive episodes. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), an atypical psychedelic, is emerging as a potentially effective, novel ...
Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała   +2 more
doaj   +3 more sources

Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. [PDF]

PLoS ONE, 2014
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-inflammatory ...
Attila Szabo, Attila Kovacs, Ede Frecska, Eva Rajnavolgyi   +3 more
doaj   +13 more sources

Reaction of N,N‑Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions [PDF]

ACS Omega, 2018
A large number of clinically used drugs and experimental pharmaceuticals possess the N,N-dimethyltryptamine (DMT) structural core. Previous reports have described the reaction of this motif with dichloromethane (DCM), a common laboratory solvent used ...
Lee E. Dunlap, David E. Olson
doaj   +4 more sources